Lee Chao to Apoptosis
This is a "connection" page, showing publications Lee Chao has written about Apoptosis.
Connection Strength
1.782
-
Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem. 2017 11 27; 398(12):1309-1317.
Score: 0.360
-
Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007 Jul; 28(7):1383-9.
Score: 0.174
-
Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension. 2007 Mar; 49(3):490-7.
Score: 0.169
-
Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol. 2006 Feb; 197(2):521-30.
Score: 0.157
-
Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp Cell Res. 2016 Jan 15; 340(2):305-14.
Score: 0.079
-
Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015 Jul 22; 5:12463.
Score: 0.076
-
Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Sep 18; 3(5):e001194.
Score: 0.072
-
Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
Score: 0.065
-
Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010 Nov; 299(5):H1419-27.
Score: 0.054
-
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
Score: 0.047
-
Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
Score: 0.047
-
Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
Score: 0.042
-
Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
Score: 0.042
-
Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
Score: 0.040
-
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
Score: 0.040
-
Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
Score: 0.039
-
Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
Score: 0.037
-
Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
Score: 0.037
-
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
Score: 0.034
-
Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004 Jan; 43(1):109-16.
Score: 0.034
-
Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
Score: 0.033
-
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
Score: 0.026
-
Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014 Jun; 142(2):216-26.
Score: 0.018
-
Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
Score: 0.016
-
Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
Score: 0.011
-
Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
Score: 0.011
-
Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr; 47(4):752-61.
Score: 0.010
-
Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
Score: 0.009